Psoriasis treatments are transforming lives

It’s a confusing time to be a psoriasis patient. If you watch TV, you are seeing a record number of advertisements about various psoriasis and psoriatic arthritis treatments. Meanwhile, worldwide media phenomenon Kim Kardashian is posting on Instagram about weird potions she is drinking, and applying to her face, to try to control her psoriasis; while on her TV show, she sought treatment advice from a quack who has made a mint pretending to “commune” with “spirits” to heal incurable diseases. Not be outdone, internet message boards, YouTube videos, and the media are overflowing with stories about the latest fad ingredient that will most definitely, certainly, “CURE” your psoriasis. Spoiler alert: it won’t.

What can get lost in this clamor is the most exciting psoriasis news in decades – and perhaps ever. For the first time, clear skin is within reach for many people living with moderate to severe plaque psoriasis, and stopping disease progression is within reach for most people with active psoriatic arthritis.

This is phenomenal and should give every person with psoriasis or psoriatic arthritis hope, and inspire them to see a dermatologist (a doctor who specializes in treating diseases related to the skin), or a rheumatologist (a doctor who specializes in joint disease), and investigate all the promising treatment options.

This progress has been driven by scientific and medical advances that have greatly expanded our understanding of the immune system’s role in psoriatic disease. This, in turn, has led to targeted therapies that have improved both safety and effectiveness over treatments available a generation ago. Today, for many people with psoriasis, 90% or more improvement of their skin symptoms is within reach; and some are achieving completely clear skin that can be maintained safely for years.

This. Is. Monumental.

Choose your path to learn more….

The Latest Psoriasis News

Experimental psoriatic arthritis treatment filgotinib shows strong response in clinical trials
Experimental psoriatic arthritis treatment filgotinib shows strong response in clinical trials

Gilead Sciences and Galapagos jointly announced results from Phase Two (mid-stage) clinical trials for their JAK1 inhibitor filgotinib for psoriatic arthritis. The companies are jointly developing the investigational treatment. JAK inhibitors, taken as pills, are receiving much attention for their ability to help people with rheumatoid arthritis (RA), psoriatic arthritis, Continue Reading…

Taltz challenges Humira in head to head clinical trial treating psoriatic arthritis
Taltz challenges Humira in head to head clinical trial treating psoriatic arthritis

Eli Lilly and Company shared new data from its 52-week, head-to-head biologic clinical trial pitting its Taltz (ixekizumab) against AbbVie’s longtime blockbuster Humira (adalimumab) in patients with psoriatic arthritis who had not yet tried a biologic. Here’s the bottom line for those of you who just want the answers without Continue Reading…

Tremfya approval in U.S. for psoriatic arthritis looks likely
Tremfya approval in U.S. for psoriatic arthritis looks likely

Tremfya (guselkumab), is approved by the U.S. Food and Drug Administration (FDA) and regulators elsewhere for the treatment of adults with moderate to severe plaque psoriasis. It is an IL-23 inhibitor that is very successful at improving skin psoriasis. It was approved in Europe in 2019 for active psoriatic arthritis, Continue Reading…